FDA Approves Daratumumab and Hyaluronidase-fihj for High-Risk Smoldering Multiple Myeloma By Ogkologos - November 13, 2025 348 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the AQUILA study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR An Updated Overview of Estimates for Cancer Incidence and Mortality in... June 23, 2022 Following Abnormal Cancer Screening Results, Multi-Level Reminders May Increase Follow-Up December 22, 2023 EMA Recommends Granting a Marketing Authorisation for Elacestrant July 26, 2023 Mutation Screening Could Reveal Whether Hormone Treatment Will Work for Breast... April 23, 2021 Load more HOT NEWS 5 Kids Battling Sickle Cell And Cancer Model Their Dream Jobs... How Fatty Liver Disease Helps Cancer Thrive in the Liver Enzalutamide Plus ADT Significantly Prolongs Survival in Patients with Metastatic Hormone-Sensitive... Help seeking: Why isn’t it as simple as it might sound?
